8 terminated. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Terminated 8 |
| Phase 2 | 1 | Terminated 1 |
Follow poly-ICLC: new trials by email Literature Review of poly-ICLC trials Research Report on poly-ICLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Neoantigen Peptide Vaccine, Poly ICLC, Blood for immune monitoring - Pancreas Cancer, Pancreatic Cancer | Phase 1 | Terminated | Washington University School of Medicine | 12 | 2020-02-13 | 2024-07-17 |
| Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma Personalized tumor vaccine, Poly ICLC, Nivolumab - Follicular Lymphoma | Phase 1 | Terminated | Washington University School of Medicine | 4 | 2018-10-16 | 2023-08-14 |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma NEO-PV-01, Nivolumab, Adjuvant - Metastatic Melanoma | Phase 1 | Terminated | BioNTech US Inc. | 22 | 2018-10-08 | 2020-09-03 |
| Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2017-11-08 | 2026-10-20 |
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) IMA950, poly-ICLC, Varlilumab - Glioma, Malignant Glioma | Phase 1 | Terminated | Nicholas Butowski | 14 | 2017-04-03 | 2024-06-14 |
| Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma Personalized peptide vaccine, Poly-ICLC, Temozolomide - Glioblastoma Multiforme, Astrocytoma, Grade IV | Phase 1 | Terminated | Washington University School of Medicine | 1 | 2015-12-03 | 2017-11-17 |
| Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer poly-ICLC, 9 Peptides from Her-2/neu, CEA, & CTA, Peptide-tet - Breast Cancer | Phase 1 | Terminated | Craig L Slingluff, Jr | 11 | 2012-07-01 | 2020-05-08 |
| Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Poly-ICLC - B Cell Lymphoma, T Cell Lymphoma | Phase 1 | Terminated | Nevada Cancer Institute | 3 | 2009-04-01 | 2011-07-20 |
Lymphoma, Follicular (2) · Astrocytoma (1) · Breast Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell (1) · Melanoma (1) · Oligodendroglioma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
Washington University School of Medicine (3) · BioNTech US Inc. (1) · Craig L Slingluff, Jr (1) · National Cancer Institute (NCI) (1) · Nevada Cancer Institute (1) · Nicholas Butowski (1)
United States (8)
Delva Deauna-Limayo, MD (1) · Gavin Dunn, M.D., Ph.D. (1) · Hideho Okada, MD, PhD (1) · Kunle Odunsi (1) · Mark DeMario, MD (1) · Nancy Bartlett, M.D. (1) · Nicholas Butowski, MD (1) · Patrick M Dillon, MD (1) · William E Gillanders, M.D. (1)
P30CA016056 (1), P50CA196510 (1), R21CA233856 (1)